Peer-reviewed veterinary case report
Cox-1 and Cox-2 enzyme levels in dog mammary tumors
By Queiroga, F L et al.·Published in Journal of comparative pathology·2007·Department of Veterinary Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Expression of Cox-1 and Cox-2 in canine mammary tumours.
- Species:
- dog
Plain-English summary
A study looked at the levels of certain enzymes in mammary tumors from dogs, finding that malignant tumors had higher levels of Cox-2 compared to benign ones. This suggests that dogs with malignant mammary tumors might benefit from treatments that include nonsteroidal anti-inflammatory drugs (NSAIDs) that target Cox-2. The research indicates that these drugs could be a helpful option in managing more aggressive types of mammary cancer in dogs.
People also search for: dog mammary tumor treatment · canine cancer NSAIDs · high Cox-2 in dog tumors
Abstract
The aim of this study was to investigate immunohistochemically the expression of cyclooxygenase-1 (Cox-1) and cyclooxygenase-2 (Cox-2) in canine mammary tumours of different histological types. Cox-1 and Cox-2 enzyme expression was evaluated in 70 mammary samples (four normal, six hyperplastic, 60 neoplastic [21 benign and 39 malignant]). Cox-1 expression was identified in all the samples, and Cox-2 in all the mammary lesions except ductal hyperplasia. Two of the four normal mammary gland samples showed focal immunoreactivity for Cox-2. Cox-1 immunoexpression did not differ significantly between benign and malignant lesions (P=0.272). Cox-2 immunoexpression was higher in malignant tumours than in benign counterparts (P<0.001). Of the malignant tumours, carcinosarcomas and tubulopapillary and squamous cell carcinomas had the highest Cox-2 scores. The study showed that malignant tumours had the highest values of Cox-2 expression, and Cox-2 immunolabelling was particularly intense in histological types classically associated with high malignancy. This suggests that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly Cox-2 inhibitors, may have a useful role to play in the treatment of canine malignant mammary tumours.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17416236/